- Jennifer Schneider Elected to Vertex Board of Directors
- Alpine Immune Sciences Reports First Quarter 2024 Financial Results
- Vertex Reports First Quarter 2024 Financial Results
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
- Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Vertex to Announce First Quarter 2024 Financial Results on May 6
- Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
- Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
More ▼
Key statistics
As of last trade Vertex Pharmaceuticals Inc (VRTX:NSQ) traded at 439.03, -2.09% below its 52-week high of 448.40, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 434.59 |
---|---|
High | 439.98 |
Low | 432.22 |
Bid | 438.89 |
Offer | 439.17 |
Previous close | 437.49 |
Average volume | 1.15m |
---|---|
Shares outstanding | 258.30m |
Free float | 258.25m |
P/E (TTM) | 27.18 |
Market cap | 108.23bn USD |
EPS (TTM) | 15.42 USD |
Data delayed at least 15 minutes, as of May 16 2024 20:05 BST.
More ▼